Amgen has gone to federal court to block Teva's path with its recent BLA filing for XM02 - a potential biosimilar competitor to Amgen's Neupogen and Neulasta. Amgen has filed a patent infringement claim against Teva in a Philadelphia court. This sets up an interesting legal battle. See full article as reported on easy bourse.
Posted by Bruce Lehr Feb 3, 2010